DDInter675 DDInter1021
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured by the company, _Ipsen Pharmaceuticals_ as lanreotide acetate, and marketed as _Somatuline_. It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007.
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Bisoprolol
Bisoprolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Insulin human {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Larotrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lanreotide
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) resembles Propafenone (Compound) and Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Lanreotide
Esmolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) resembles Metoprolol (Compound) and Metoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide
Esmolol (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide